Legislation pending in Congress would remove marijuana from the list of substances in the Controlled Substances Act, resulting in repeal of the income tax disallowance of deductions for marijuana businesses, currently unable to deduct business expenses
Legislation pending in Congress would remove marijuana from the list of substances in the Controlled Substances Act, resulting in repeal of the income tax disallowance of deductions for marijuana businesses, currently unable to deduct business expenses
Curaleaf Reports Record Fourth Quarter and Fiscal Year End 2020 Financial and Operational Results
Record Fiscal Year and Fourth Quarter 2020 Pro Forma Revenue(1)(2) of $767.1 Million and $238.8 Million, Respectively
Record Fiscal Year and Fourth Quarter 2020 Managed Revenue(1) of $653.0 Million, up 161% from 2019 and $233.3 Million, up 186% from 2019, Respectively
Record Fiscal Year and Fourth Quarter 2020 Adjusted EBITDA(1) of $144.1 Million up 456% from 2019 and $53.8 Million up 289% from 2019, Respectively, as Operations Across 23 States Continue to Scale
Raised $289.8 Million of Net Proceeds from a Common Stock Offering and Debt Offering in January 2021, Providing the Company with Capital to Pursue Additional Organic and Inorganic Growth Opportunities
News provided by
Share this article